• US: +1-408-610-2300
  • Toll Free: +1-866-831-4085
  • Login / Register
  • Home
  • » Generic Drugs
  • » Dyslipidemia Drugs Market Size & Share, 2018 | Industry Trends Report
Dyslipidemia Drugs Market Size & Share, 2018 | Industry Trends Report

Dyslipidemia Drugs Industry 2018 Market Research Report

Report ID: MN17614999  |  Published: August 2017  |  No of Pages: 112
Format: Electronic (PDF)  |  Industry: Generic Drugs  |  Publisher: QY Research

Global Dyslipidemia Drugs Market is expected to grow at a significant CAGR in the upcoming years as the scope and its applications are increasing across the globe. Dyslipidemia is a chronic metabolic syndrome that refers to an abnormal level of blood lipids wherein there may be either lipoprotein overproduction or deficiency.

Dyslipidemia can affect any lipid parameter such as HDL cholesterol levels, LDL cholesterol levels, triglycerides, or a combination of these lipids. There are numerous causes of Dyslipidemia such as mutated genes, diabetes, poor or high fat, liver diseases, alcohol abuse, cigarette smoking, etc. There are various types of drugs available in the market to treat Dyslipidemia namely Bile Acid Resins, Niacins, Statins, etc. The treatment of Dyslipidemia also include exercise, reduced saturated fats in the diet, etc.

The key factors that propel the growth of the Dyslipidemia Drugs Market include increasing demand, growing awareness among people, changing lifestyle, and rising research & development undertakings. In addition, some of the other factors such as obesity, high prevalence of abnormalities associated with, triglyceride & cholesterol, intake of unhealthy food, and lack of physical activities also fuel the market growth.

On the other hand, there are also factors that may hamper the growth of the market such as patent expiry. Dyslipidemia Drugs Market is classified on the basis of product type, applications, distribution channel and geography. Dyslipidemia Drugs Market is segmented by product type as Combination Drugs, Bile Acid Resins, Fibric Acid and Omega-3 Fatty Acid Derivatives, Niacins, Statins, and others.

Dyslipidemia Drugs Industry is classified on applications as hospital pharmacies, retail pharmacies, online pharmacies and others. Dyslipidemia Drugs Market is classified on the basis of geography as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, Japan and Middle East and Africa.

The North American region consists of the U.S., and Canada. Latin America region consists of Mexico and Brazil. The Western European region consists of Germany, Italy, France, England and Spain. The Eastern European region consists of Poland and Russia. Asia Pacific region consists of China, India, ASEAN, and Australia & New Zealand. The Middle East and African region consists of GCC, South Africa and North Africa.

Some of the key players that fuel the growth of the Dyslipidemia Drugs Market include AstraZeneca, Abbott Laboratories, Amgen, Bristol-Myers Squibb Company, Bayer, Merck, Mylan, Novartis, Pfizer, Shionogi, Takeda Pharmaceutical, Teva Pharmaceutical, and others. The key players are focusing on inorganic growth to sustain themselves amidst fierce competition. As such, mergers, acquisitions, and joint ventures are the need of the hour.

Market Segment:

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Dyslipidemia Drugs in these regions, from 2013 to 2025 (forecast), covering
• North America
• Europe
• China
• Japan
• Southeast Asia
• India

Global Dyslipidemia Drugs market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
• AstraZeneca
• Merck
• Pfizer
• Bayer
• Abbott Laboratories
• Mylan
• Novartis
• Amgen
• Bristol-Myers Squibb Company
• Shionogi
• Takeda Pharmaceutical
• Teva Pharmaceutical

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
• Statins
• Bile Acid Resins
• Fibric Acid and Omega-3 Fatty Acid Derivatives
• Niacins
• Combination Drugs
• Cholesterol Absorption Inhibitors

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

What questions do you have? Get quick response from our industry experts. Request More information
Key questions answered in the report include
key questions
We also offers customization on reports based on specific client requirement.
Request for Customization

Choose License Type

Research Assistance

Ryan Manuel
Ryan Manuel

Research Support Specialist, USA

  1. Phone: +1-408-610-2300
  2. Toll Free: +1-866-831-4085
  3. Email: [email protected]
  • World's largest premium report database
  • Transparent pre & post sale customer engagement model
  • Unparalleled flexibility in terms of rendering services
  • Safe & secure web experience
  • 24*5 Research support service
  • 100% Secure Payments
  • Our Promise
  • 100% Service Assurance
  • Market Monitoring
  • Service Flexibility
  • 24X5 Care available